224 related articles for article (PubMed ID: 18317884)
1. In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine.
Takeda M; Tada H; Higuchi H; Kobayashi Y; Kobayashi M; Sakurai Y; Ishida T; Ohuchi N
Breast Cancer; 2008; 15(2):145-52. PubMed ID: 18317884
[TBL] [Abstract][Full Text] [Related]
2. [In vivo single molecular fluorescence imaging for analysis of pharmacokinetics].
Takeda M; Gonda K; Higuchi H; Ohuchi N
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1277-80. PubMed ID: 18701837
[TBL] [Abstract][Full Text] [Related]
3. Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast cancer mouse model.
Wu J; Ma R; Cao H; Wang Z; Jing C; Sun Y; Zhang Y; Yang Z; Hoffman RM; Tang J
Anticancer Res; 2013 Feb; 33(2):419-24. PubMed ID: 23393332
[TBL] [Abstract][Full Text] [Related]
4. Multilayered, core/shell nanoprobes based on magnetic ferric oxide particles and quantum dots for multimodality imaging of breast cancer tumors.
Ma Q; Nakane Y; Mori Y; Hasegawa M; Yoshioka Y; Watanabe TM; Gonda K; Ohuchi N; Jin T
Biomaterials; 2012 Nov; 33(33):8486-94. PubMed ID: 22906608
[TBL] [Abstract][Full Text] [Related]
5. Nano-imaging of the lymph network structure with quantum dots.
Hikage M; Gonda K; Takeda M; Kamei T; Kobayashi M; Kumasaka M; Watanabe M; Satomi S; Ohuchi N
Nanotechnology; 2010 May; 21(18):185103. PubMed ID: 20388975
[TBL] [Abstract][Full Text] [Related]
6. In vivo imaging of quantum dots.
Texier I; Josser V
Methods Mol Biol; 2009; 544():393-406. PubMed ID: 19488714
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence nanoparticles "quantum dots" as drug delivery system and their toxicity: a review.
Ghaderi S; Ramesh B; Seifalian AM
J Drug Target; 2011 Aug; 19(7):475-86. PubMed ID: 20964619
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node imaging using quantum dots in mouse tumor models.
Ballou B; Ernst LA; Andreko S; Harper T; Fitzpatrick JA; Waggoner AS; Bruchez MP
Bioconjug Chem; 2007; 18(2):389-96. PubMed ID: 17263568
[TBL] [Abstract][Full Text] [Related]
9. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
10. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
Steinhauser I; Spänkuch B; Strebhardt K; Langer K
Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
[TBL] [Abstract][Full Text] [Related]
12. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.
Vaneycken I; Devoogdt N; Van Gassen N; Vincke C; Xavier C; Wernery U; Muyldermans S; Lahoutte T; Caveliers V
FASEB J; 2011 Jul; 25(7):2433-46. PubMed ID: 21478264
[TBL] [Abstract][Full Text] [Related]
13. Targeting her-2/neu with antirat Neu virosomes for cancer therapy.
Waelti E; Wegmann N; Schwaninger R; Wetterwald A; Wingenfeld C; Rothen-Rutishauser B; Gimmi CD
Cancer Res; 2002 Jan; 62(2):437-44. PubMed ID: 11809693
[TBL] [Abstract][Full Text] [Related]
14. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
[TBL] [Abstract][Full Text] [Related]
15. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
16. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
17. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery.
Lu RM; Chang YL; Chen MS; Wu HC
Biomaterials; 2011 Apr; 32(12):3265-74. PubMed ID: 21306768
[TBL] [Abstract][Full Text] [Related]
18. Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles.
Tan YF; Chandrasekharan P; Maity D; Yong CX; Chuang KH; Zhao Y; Wang S; Ding J; Feng SS
Biomaterials; 2011 Apr; 32(11):2969-78. PubMed ID: 21257200
[TBL] [Abstract][Full Text] [Related]
19. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives.
Zhang H; Yee D; Wang C
Nanomedicine (Lond); 2008 Feb; 3(1):83-91. PubMed ID: 18393668
[TBL] [Abstract][Full Text] [Related]
20. Multicolor core/shell silica nanoparticles for in vivo and ex vivo imaging.
Rampazzo E; Boschi F; Bonacchi S; Juris R; Montalti M; Zaccheroni N; Prodi L; Calderan L; Rossi B; Becchi S; Sbarbati A
Nanoscale; 2012 Feb; 4(3):824-30. PubMed ID: 22159192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
